Trade Pfizer ^PFE

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook

Pfizer (NYSE:PFE) Price Target Raised to $36.00

Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC

Park Place Capital Corp Trims Position in Pfizer Inc. $PFE

Organon: A High Cash Yield Hidden Behind Patent Fatigue | Investing.com Canada

Pfizer and Valneva's Lyme Disease Vaccine Demonstrates Over 70% Efficacy in Key Trial, ETPharma

Enhanced dynamic risk stratification of smoldering multiple myeloma

Pfizer working to get approval on new Lyme disease vaccine. Expert says tick activity rising in New England. - CBS Boston

Pfizer says Lyme disease vaccine is holding promise - CBS Boston

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story

Health Care Up, but Not by Much, Amid Cyclical Rotation - Health Care Roundup | Morningstar

Dow Jones Top Company Headlines at 3 PM ET: Danone to Buy Protein-Shake Maker Huel for $1.2 Billion | Toyota ... | Morningstar

Is Pfizer (PFE) Offering Value After Its Post Covid Portfolio Shift And Mixed Returns?

Valneva Shares Plunge 36% Over Lyme Vaccine Phase 3 Data

Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why - Markets Daily

Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial | Euronews

Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

Pfizer says long-awaited Lyme vaccine was effective in study

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l'essai de Phase 3 VALOR

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial | Morningstar

Goodman Financial Corp Purchases 137,772 Shares of Pfizer Inc. $PFE

2 Unpopular Stocks That Should Get More Attention and 1 We Avoid

Pfizer, Valneva post mixed results for Lyme disease vaccine | BioWorld

IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ...

Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis

Tencent: The Premier Hunter of Medical IPOs

Tencent: Der Superjäger für medizinische Börsengänge

Pfizer Inc. $PFE Stock Holdings Increased by Park Avenue Securities LLC

Sound View Wealth Advisors Group LLC Has $1.43 Million Position in Pfizer Inc. $PFE - Daily Political

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook

Novo Nordisk's GLP-1 Leadership Tested By FDA Warnings And Rising Rivals

6 years since lockdown, here's a look at COVID vaccine guidance today - Yahoo News Canada

BCGM Wealth Management LLC Takes Position in Pfizer Inc. $PFE

Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook

Pfizer (NYSE:PFE) Stock Price Down 1.6% - Should You Sell?

Company Website: https://www.pfizer.com NEW YORK -- (Busin

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

My Top 3 Drug Stocks for March 2026

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

HHS ​chief counselor says encouraged by candidates vying to lead CDC - Yahoo News Canada

Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer's Oncology Story And Investment Case (PFE)?

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can't Ignore

Is It Too Late to Buy Eli Lilly?

Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement

Promising Pharmaceutical Stocks To Research - March 19th - Daily Political

AIA Group Ltd Has $12.31 Million Stock Holdings in Pfizer Inc. $PFE

Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels

Protalix Stock Down As FY25 Results Show Net Loss, Fabry Milestones Boosts Outlook

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS)

Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

Valneva Q4 Earnings Call Highlights - Stock Observer

Dividend Stocks To Follow Now - March 18th - Stock Observer

Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology

20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style

Captrust Financial Advisors Cuts Stake in Pfizer Inc. $PFE

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Valneva gibt die konsolidierten geprüften Finanzergebnisse für das Gesamtjahr 2025 bekannt

Maven Securities LTD Sells 22,785 Shares of Pfizer Inc. $PFE - Daily Political

Danske Bank A S Acquires Shares of 3,190,647 Pfizer Inc. $PFE - Daily Political

Thymic health and immunotherapy outcomes in patients with cancer

Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study

Thymic health consequences in adults

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results

Jim Cramer Notes Pfizer (PFE) Has "Got a Lot of Stuff in the Pipeline"

Pfizer (NYSE:PFE) Trading 3.2% Higher Following Analyst Upgrade

Pfizer (NYSE:PFE) Price Target Raised to $32.00

CSPi Enhances Board of Director Capabilities with Addition of Cybersecurity Expert | Morningstar

Dividend Stocks To Watch Today - March 17th - Daily Political

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer's Atirmociclib Meets Primary Endpoint In Phase 2 FOURLIGHT-1 Breast Cancer Trial

National Bank of Canada FI Decreases Stake in Pfizer Inc. $PFE

Jain Global LLC Boosts Stake in Pfizer Inc. $PFE

Focus Partners Wealth Acquires 551,274 Shares of Pfizer Inc. $PFE

CT cannot afford to delay the Southeast Resiliency Project

Pfizer Inc. $PFE Shares Purchased by Jain Global LLC - Daily Political

Pfizer Inc. $PFE Shares Bought by Gotham Asset Management LLC - Markets Daily

Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift? - Simply Wall St News

First Western Trust Bank Has $569,000 Position in Pfizer Inc. $PFE - Markets Daily

Gotham Asset Management LLC Grows Position in Pfizer Inc. $PFE

Destination Wealth Management Has $21.92 Million Position in Pfizer Inc. $PFE - Markets Daily

Ameriprise Financial Inc. Increases Holdings in Pfizer Inc. $PFE

Pfizer Inc. $PFE Stake Reduced by First Western Trust Bank - Stock Observer

Is Pfizer Inc. (PFE) A Good Stock To Buy Now?

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?

Pfizer Pipeline Updates Test Valuation Gap As New Trials Begin

Pfizer Inc. $PFE Shares Sold by CSM Advisors LLC

Community Bank N.A. Has $1.60 Million Holdings in Pfizer Inc. $PFE - Stock Observer

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Trump Announces 25% Tariffs on Automobiles, Pharmaceuticals, and Semiconductors

Week Ahead: US And Canada Labour Markets Are In Focus, BoE Rate Decision

Stock price forecast: 4 S&P 500 Stocks for 2025

Week ahead: Apple leads big tech earnings, UK Budget and Nonfarm Payrolls

Week ahead: Apple earnings land as Fed seen holding rates

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk